MetaVia Posts 2025 Loss, Advances Obesity Drug DA-1726
Event summary
- MetaVia reported a net loss of $13.0 million for the year ended December 31, 2025, compared to $27.6 million in 2024.
- The company raised $9.3 million in a public offering in January 2026.
- Phase 1 data for DA-1726 demonstrated 9.1% weight loss, improved glucose control, and liver benefit without titration.
- IRB approval was received for a 16-week titration study of DA-1726, expected to begin in April 2026 with data in Q4 2026.
- Phase 2a data for vanoglipel (DA-1241) showed improvements in glucose control, liver health, and lipidomic profiles.
The big picture
MetaVia is positioned within a rapidly evolving obesity treatment landscape dominated by GLP-1 receptor agonists. DA-1726's dual-agonist mechanism and reported benefits beyond weight loss – including improved glucose control and liver health – represent a potential competitive advantage, but require validation in later-stage trials. The company's reliance on licensing agreements, particularly with Dong-A ST, introduces a degree of dependency and potential negotiation risk.
What we're watching
- Clinical Execution
- The success of the upcoming Phase 1 titration study for DA-1726 will be critical in validating the initial Phase 1 data and informing dose selection for future trials, potentially impacting the drug's commercial viability.
- Regulatory Pathway
- The timing and outcome of MetaVia's planned end-of-Phase 2 meeting with the FDA regarding vanoglipel will significantly influence the drug's progression towards potential approval and market entry.
- Financial Runway
- While the recent public offering extends MetaVia's cash runway into Q4 2026, continued funding will be necessary to support ongoing clinical trials and development programs, potentially requiring further capital raises.
Related topics